Neuropace Inc. (NPCE) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for NPCE, including 1 earnings update. The most recent was published Oct 29, 2026.
NPCE rankings
Financial highlights
Full financials- Revenue, TTM
- $98.84M
- Revenue growth
- +16.9%
- Net income, TTM
- -$19.11M
- Net margin
- -19.3%
- Free cash flow, TTM
- -$11.61M
- Cash
- $12.54M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks35-50%
2026-05-172026-11-08
Mix1390d
- Insider5(38%)
- Other3(23%)
- Earnings2(15%)
- SEC Filings2(15%)
- Analyst1(8%)
Activity · 52 weeks7343 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRNeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing +1 833-461-5787 and referencing Conference ID 345 741 415. The webcast will be archived on the company’s i
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERChief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)4 - NeuroPace Inc (0001528287) (Issuer)
- ANALYSTKeyBanc Capital Markets initiated coverage on NeuroPace with a new price targetKeyBanc Capital Markets initiated coverage of NeuroPace with a rating of Overweight and set a new price target of $18.00
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,310 shares, decreasing direct ownership by 0.94% to 138,000 units (SEC Form 4) (for tax liability)4 - NeuroPace Inc (0001528287) (Issuer)
- PRNeuroPace to Participate in 2026 Cantor Global Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medi
- PRNeuroPace to Participate in Wells Fargo 21st Annual Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a me
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.80% to 139,310 units (SEC Form 4) to satisfy withholding obligation4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.69% to 51,692 units (SEC Form 4) (for withholding tax)4 - NeuroPace Inc (0001528287) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)
- SECSEC Form 10-Q filed by Neuropace Inc.10-Q - NeuroPace Inc (0001528287) (Filer)
- SECNeuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth-- --Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS® revenue from existing indications-- --Preparation remains on track for SIR meeting with FDA regarding the IGE PMA supplement, supported by 24-month NAUTILUS data showing a 100% median reduction in GTC seizures among evaluable patients1-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corpor
- SECNeuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and literature supporting the submission has been requested -- -- FDA has invited continued dialogue, and NeuroPace will be submitting a Submission Issue Request and intends to continue working with FDA on a path for approval of the submission -- -- Management will host a conference call to discuss this communication from the FDA at 4:30pm E.T./1:30pm P.T. -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epile
- ANALYSTMizuho initiated coverage on NeuroPace with a new price targetMizuho initiated coverage of NeuroPace with a rating of Outperform and set a new price target of $22.00
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.64% to 52,050 units (SEC Form 4) to satisfy withholding obligation4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Geiger Uri was granted 789 shares, increasing direct ownership by 4% to 18,537 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Fischer Frank M was granted 1,467 shares, increasing direct ownership by 0.25% to 599,534 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Kumar Rakhi was granted 989 shares, increasing direct ownership by 4% to 23,039 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- SECSEC Form 8-K filed by Neuropace Inc.8-K - NeuroPace Inc (0001528287) (Filer)
- INSIDERDirector Huennekens R Scott was granted 2,890 shares (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Fischer Frank M was granted 2,890 shares, increasing direct ownership by 0.49% to 598,067 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Geiger Uri was granted 2,890 shares, increasing direct ownership by 19% to 17,748 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Kumar Rakhi was granted 2,890 shares, increasing direct ownership by 15% to 22,050 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
NPCE FAQ
11 questionsWhat does Neuropace Inc. do?
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in...What is the latest news on NPCE?
In the last 30 days Quantisnow tracked 1 wire item for NPCE: 1 earnings update. The most recent was published on October 29, 2026.What is NPCE revenue?
Neuropace Inc. (NPCE) reported $98.84M of revenue for the twelve months ended Jun 30, 2026. That is up 16.9% from the year before. Revenue for fiscal 2025 was $99.99M.Is NPCE profitable?
No. Neuropace Inc. reported a net loss of $19.11M for the twelve months ended Jun 30, 2026.How much cash and debt does NPCE have?
Neuropace Inc. reported $12.54M in cash and cash equivalents and $59.01M of debt on its most recent balance sheet in SEC filings.Where does NPCE stock trade?
Neuropace Inc. (NPCE) is listed on NASDAQ.What sector and industry is NPCE in?
Neuropace Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Neuropace Inc. go public?
Neuropace Inc. (NPCE) completed its IPO in 2021.What are analysts saying about NPCE?
Across the last 8 analyst actions on Neuropace Inc., there were 2 upgrades and 0 downgrades. The most recent action was from KeyBanc Capital Markets: Overweight with a $18.00 price target on 2026-09-18. Recent price targets range from $6.00 to $22.00.What companies are similar to NPCE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare NPCE side-by-side with any of them on Quantisnow.How can I track NPCE on Quantisnow?
Quantisnow aggregates Neuropace Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NPCE to receive live email and push alerts on every new disclosure.